Artificial intelligence medical imaging is a golden track. After Eagle Hitomi Technology hits the Hong Kong Stock Exchange, it will become the “first stock in medical AI”. The concept is very good.
I. Prospectus Information
II. Company Overview
Eagle Eye Technology, from Beijing, was founded in 2015. It is one of the first companies in China to provide non-invasive, fast, effective, and scalable early detection, diagnosis and health risk assessment solutions for artificial intelligence retinal image recognition.
The company has three versions of AirDoc-aifundus (independently developed core product) in its product portfolio. Among them, AirDoc-aifundus (1.0) is an artificial intelligence medical device software (SaMD), approved to assist doctors in diagnosing diabetic retinopathy to assist doctors in making medical diagnoses. It is the first medical device of its kind to obtain a Class III medical device certificate from the State Drug Administration. The product has been generating revenue since the first quarter of 2021.
According to financial data, in 2019 and 2020, Eagle Hitomi Technology's revenue was 34.15 million yuan and 476.72 million yuan respectively; in the first half of 2021, Eagle Hitomi Technology achieved revenue of 49.477 million yuan, exceeding last year's full revenue.
In 2019, 2020, and the first half of 2021, Eagle Hitomi Technology's net losses were 87.139 million yuan, 796.26 million yuan, and 37.49 million yuan respectively, and the loss gradually narrowed.
It is worth mentioning that the revenue brought by SaMD to the company accounted for the highest share of revenue, accounting for in 2019...